scholarly journals Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy

2004 ◽  
Vol 88 (6) ◽  
pp. 809-815 ◽  
Author(s):  
M Matsuoka
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Polypoidal Choroidal Vasculopathy ◽  
Pigment Epithelium ◽  
Vascular Endothelial ◽  
Pigment Epithelium Derived Factor ◽  
Endothelial Growth Factor ◽  
Choroidal Vasculopathy

scholarly journals Addition of photodynamic therapy to anti-vascular endothelial growth factor drugs compared to anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy

Medwave ◽  
2021 ◽  
Vol 21 (08) ◽  
pp. e8460-e8460
Author(s):  
Franco Manzur Yarur ◽  
Victor Meza V ◽  
Rodolfo Garretón C ◽  
Aldo Muñoz Q
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Photodynamic Therapy ◽  
Growth Factor ◽  
Systematic Reviews ◽  
Polypoidal Choroidal Vasculopathy ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Choroidal Vasculopathy

Introduction Polypoidal choroidal vasculopathy is characterized by multiple and recurrent serosanguineous detachments of the retinal pigment epithelium and aneurysmal protrusions in the choroidal vessels. Different therapeutic options have been proposed, including anti-vascular endothelial growth factor drugs and photodynamic therapy. Controversy exists as to whether combination therapy is superior to anti-vascular endothelial factor drugs alone. Methods We searched Epistemonikos, the largest database of systematic reviews in health, maintained by screening multiple sources of information, including MEDLINE/PubMed, EMBASE, and Cochrane. We extracted data from the identified reviews, analyzed the data from the primary studies, performed a meta-analysis, and prepared a summary table of the results using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method. Results We identified three systematic reviews that together included twelve primary studies. Of these, two were randomized trials, and only one of them was included in the analysis. Conclusions The addition of photodynamic therapy may result in little or no difference in the incidence of retinal hemorrhage and visual acuity gain at six months (low certainty of evidence). On the other hand, the combination of photodynamic therapy and anti-vascular endothelial growth factor drugs compared to anti-vascular endothelial growth factor alone is likely to increase polyp regression at three and six months and reduce central retinal thickness at six months.

Sign in / Sign up

Export Citation Format

Share Document